European Leukemia Trial Registry
Trial: OPTIC

More Details
Title AP24534-14-203
Scientific Title Ponatinib in Patients With Resistant Chronic Phase Myeloid Leukemia (CML) to Characterize the Efficancy and Safety of a Range of Doses (OPTIC)
Short Title OPTIC
Trialgroup NN
Type of Trial multicentric, randomized, prospective, open-label
Disease Chronic myeloid leukemia(CML) Chronic Phase
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.06.2015
Leader Hochhaus, Prof. Dr. med., Andreas
Centre of Trial Universitätsklinikum Jena, Klinik für Innere Medizin II, Abt. Hämatologie und Internistische Onkologie
Shortprotocol Shortprotocol
Remark CML Studiengruppe, CP-CML, resistent gegen 2 oder mehr TKI
created 31.07.2015 Hanna Ebert
changed 06.05.2020 Zenawit Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org